PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION ROUTE OF ADMINISTRATION • Segmentation by route of administration • Comparison by Route of Administration • Parenteral – Market size and forecast 2017-2022 • Inhalation • Market opportunity by RoA PART 08: CUSTOMER LANDSCAPE PART 09: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast 2017-2022 • EMEA – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12: MARKET TRENDS PART 13: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 14: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • CSL • GRIFOLS • Kamada • Shire PART 15: PIPELINE ANALYSIS • Pipeline analysis PART 16: APPENDIX • List of abbreviations Exhibit 01: Global alpha-1 antitrypsin drugs market – Market characteristics Exhibit 02: Global alpha-1 antitrypsin drugs market – Market segments Exhibit 03: Global alpha-1 antitrypsin drugs market – Market definition - Inclusions and exclusions checklist Exhibit 04: Global alpha-1 antitrypsin drugs market – Market size 2017 Exhibit 05: Validation techniques employed for market sizing 2017 Exhibit 06: Global alpha-1 antitrypsin drugs market – Market size and forecast 2017-2022 ($ mn) Exhibit 07: Global alpha-1 antitrypsin drugs market – Year-over-year growth 2018-2022 (%) Exhibit 08: Five forces analysis 2017 Exhibit 09: Five forces analysis 2022 Exhibit 10: Global alpha-1 antitrypsin drugs market – Bargaining power of buyers Exhibit 11: Global alpha-1 antitrypsin drugs market – Bargaining power of suppliers Exhibit 12: Global alpha-1 antitrypsin drugs market – Threat of new entrants Exhibit 13: Global alpha-1 antitrypsin drugs market – Threat of substitutes Exhibit 14: Global alpha-1 antitrypsin drugs market – Threat of rivalry Exhibit 15: Market condition – Five forces 2017 Exhibit 16: Route of Administration – Market share 2017-2022 (%) Exhibit 17: Comparison by Route of Administration Exhibit 18: Parenteral RoA - Market size and forecast 2017-2022 ($ mn) Exhibit 19: Parenteral RoA – Year over year growth 2018-2022 (%) Exhibit 20: Market opportunity by RoA Exhibit 21: Global alpha-1 antitrypsin drugs market - Customer landscape Exhibit 22: Global alpha-1 antitrypsin drugs market – Market share by geography 2017-2022 (%) Exhibit 23: Global alpha-1 antitrypsin drugs market – Regional comparison Exhibit 24: Americas – Market size and forecast 2017-2022 ($ mn) Exhibit 25: Americas – Year-over-year growth 2018-2022 (%) Exhibit 26: EMEA – Market size and forecast 2017-2022 ($ mn) Exhibit 27: EMEA – Year-over-year growth 2018-2022 (%) Exhibit 28: APAC – Market size and forecast 2017-2022 ($ mn) Exhibit 29: APAC – Year-over-year growth 2018-2022 (%) Exhibit 30: Global alpha-1 antitrypsin drugs market – Market opportunity Exhibit 31: Vendor landscape Exhibit 32: Landscape disruption Exhibit 33: Vendors covered Exhibit 34: Vendor classification Exhibit 35: Market positioning of vendors Exhibit 36: CSL overview Exhibit 37: CSL – Business segments Exhibit 38: CSL – Organizational developments Exhibit 39: CSL – Geographic focus Exhibit 40: CSL – Segment focus Exhibit 41: CSL – Key offerings Exhibit 42: GRIFOLS overview Exhibit 43: GRIFOLS – Business segments Exhibit 44: GRIFOLS – Organizational developments Exhibit 45: GRIFOLS – Geographic focus Exhibit 46: GRIFOLS – Segment focus Exhibit 47: GRIFOLS – Key offerings Exhibit 48: Kamada overview Exhibit 49: Kamada – Business segments Exhibit 50: Kamada – Organizational developments Exhibit 51: Kamada – Segment focus Exhibit 52: Kamada – Key offerings Exhibit 53: Shire – overview Exhibit 54: Shire – Business segments Exhibit 55: Shire – Organizational developments Exhibit 56: Shire – Geographic focus Exhibit 57: Shire – Segment focus Exhibit 58: Shire – Key offerings